1. Scrip
  2. >>Business
  3. >>Financing

Finance Watch: SpringWorks, Satsuma Launch IPOs; BioNTech Filing Shows US-China Trade War Impact

 
• By Mandy Jackson

BioNTech has plenty of cash and is gearing up for an IPO, but money from a Hong Kong investor is in limbo. Plus, Satsuma and SpringWorks bring US IPO total to 34 this year, Fate's FOPO raises $150.5m and Pharvaris brings in $66m.

Finance Watch

There are a lot of notable financial disclosures in BioNTech AG's US Securities and Exchange Commission (SEC) filing indicating that the company may raise up to $100m in a future initial public offering, including the fact that the four-year-old German firm has raised $1.3bn to date from seed and venture capital financings and fees from its big pharma partners.

But one particularly eye-catching footnote in the F-1 statement filed on 9 September is that Mainz-based BioNTech has yet to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Finance Watch: Lila Sciences Raises $235m To Refine Its AI Factories For Drugs And More

 
• By Mandy Jackson

Private Company Edition: Flagship’s Lila secures big series A cash six months after $200m seed funding announced in March. Also, Reunion Neuroscience increases its series A to $133m, Dualitas launches with $65m and Tasca grows its series A to $67m as its lead drug enters Phase I/II.

Ollin Launches With $100m, Two Eye Drugs And Plans To Acquire More

 
• By Mandy Jackson

The start-up, which spent two years operating in stealth mode, has a clinical-stage anti-VEGF/Ang2 drug to rival Roche’s Vabysmo, and is on the hunt for additional ophthalmology assets.

GSK Unveils Multi-Billion US Investment As Trump Visits UK

 
• By Andrew McConaghie

The UK-headquartered company is investing heavily in the US, with CEO Emma Walmsley among business leaders greeting President Trump on his state visit to the country.

Finance Watch: LB Pharmaceuticals Launches Second-Largest Biopharma IPO Of 2025 In The US

 
• By Mandy Jackson

Public Company Edition: The neuropsychiatric disease-focused firm grossed $285m in the first IPO in the US above $100m since February. Also, Avidity raised $600m in a follow-on offering, Alnylam priced a $575m note sale and Propanc joins MEI in biopharma’s cryptocurrency ranks.

More from Business

Why India Revoked The Entresto Patent And Novartis Abstained From Proceedings

 
• By Anju Ghangurde

India revokes Novartis's patent pertaining to Entresto, upholding the objections of opponents including the Indian Pharmaceutical Alliance on lack of novelty and prior claiming, among others. Novartis decided against participating in the hearings.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: GSK announces US investments during Trump’s UK visit; Lilly thinks twice about UK lab investment; analyzing the rise in China R&D and deals; Regeneron CEO on his company’s ignored blockbusters; and AstraZeneca’s COPD trial failure.

Deal Watch: Biogen Acquires Intrathecal Delivery Specialist Alcyone

 
• By Joseph Haas

Plus deals involving Frame Bio/Mercury Bio, Arch Biopartners/Lidpro, Lilly/Remedium, Cadrenal/eXIthera, Vertex/Enlaza and more.